This is the authors' abstract. We don't add key points for this paper.
One RSVPreF3 OA dose elicited cell-mediated and RSV-A- and RSV-B-specific humoral immune responses that declined over time but remained above pre-dose 1 levels for at least 1 year. The vaccine was well tolerated with an acceptable safety profile. Clinical Trials Registration. NCT04732871 (ClinicalTrials.gov).
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Schwarz et al. (2023) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: